Last reviewed · How we verify
NCT06156787
Patterns of Urinary Bladder Cancer in Darfur, Suda
trial in Urinary Bladder Cancer in 105 participants. Completed in 10 April 2022.
1 April 2022
Quick facts
| Lead sponsor | National Center for Gastroentestinal and Liver Disease |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 105 |
| Start date | 1 November 2020 |
| Primary completion | 1 April 2022 |
| Estimated completion | 10 April 2022 |
| Sites | 1 location across Sudan |
Conditions studied
- Urinary Bladder Cancer — all drugs for Urinary Bladder Cancer →
Sponsor
National Center for Gastroentestinal and Liver Disease
Who can join
18 and older, any sex, with Urinary Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: Bladder cancer (BC) exhibits extreme heterogeneity regarding clinical outcome, etiology, histology, and geographic distribution. Recent clinical observations point to alterations in the BC pattern in the Sudan, possibly as a result of lifestyle changes brought on by the enormous migration from rural to urban locations. This study aimed to identify the pattern of bladder cancer in Darfur. Patients and Methods: A cross sectional, hospital-based study, it was conducted inNyala specialized hospital, during the period from (2020 to 2022), included one hundred and five patients with bladder mass matching the inclusion criteria were studied over the diversity of demographic data , clinical finding, pathological type and possible risk factors .
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06156787
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Urinary Bladder Cancer
Currently open trials in the same condition.
- NCT07165236 — Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor · recruiting
- NCT05644041 — Intravesical Gem/Doce in Patients With NMIBC · Phase 2 · recruiting
- NCT05822934 — Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urina · Phase 3 · active not recruiting
- NCT05621837 — Quantifying Systemic Immunosuppression to Personalize Cancer Therapy · recruiting
- NCT05072600 — Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer · Phase 2 · recruiting
Other National Center for Gastroentestinal and Liver Disease trials
Trials by the same sponsor.
- NCT06360484 — Prevalence and Clinical Characterization of Hepatitis D Virus (HDV) Infection Among Sudanese Patients With Hepatitis B V · completed
- NCT07143435 — Endoscopic Findings in Iron Deficiency Anemia: A Cross-Sectional Study From Port Sudan · completed
- NCT06158308 — Outcome of Laparoscopic Appendicectomy Versus Open Appendicectomy in Sudanese Patients · completed
- NCT07143422 — Sharp Risks in a Time of Crisis: Needle-Stick Injuries in Eastern Sudan Healthcare · completed
- NCT06147115 — The Validation of Rockall Scoring System in Predicting Outcomes From Variceal Bleeding · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06156787 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Center for Gastroentestinal and Liver Disease
- Last refreshed: 5 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06156787.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing